NCT04120805Completed
Randomized Evaluation of Patients Who Have Had Laparoscopic Partial Nephrectomy
Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the necessity of using hemostatic agents as a tool when performing robotic partial nephrectomy in the treatment of kidney cancer. This project asks whether patients who undergo robotic partial nephrectomy without the surgeon using hemostatic agents during the procedure will have the same, fewer, or more complications than when patients undergo this same surgery with the surgeon using hemostatic agents during the procedure.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 208 (actual)
- First submitted
- 14 Jan 2019
- Start date
- 1 Jan 2016
- Primary completion date
- 8 Apr 2025
- Lead sponsor
- University of Chicago
- Diseases
- Kidney cancer
- NCT number
- NCT04120805
What you commit to
- Study type: Interventional
- Participants enrolled: 208
- From 1 Jan 2016 to the primary completion date, 8 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have had a renal transplantation.
- Patients on therapeutic anticoagulation prior to surgery (example anticoagulants include: aspirin 325 mg daily, clopidogrel, warfarin, fondaparinux, dabigatran, and rivaroxaban). However, patients who take aspirin 81 mg daily as their daily regimen will be included.
- Patients who have had a prior surgical procedure, aside from percutaneous renal biopsy, on the kidney in the current operation.
- Patients with over 100 mL of estimated blood loss (calculated by anesthesia team using the suction canisters) prior to clamping of the renal hilum will be excluded.
Lab values
- Patients with bleeding disorders (example: hemophilia) and other documented coagulopathy (example: chronic liver disease) with INR greater than 1.0 at baseline.
Other
- Patients on hemodialysis.
Who the study is looking for
- Male and female patients aged 18 years and older.
- Patients must have a solid or cystic renal mass suspicious for malignancy by imaging with ultrasound, computed tomography (CT) scan, or magnetic resonance imaging (MRI).
- Patients must be initially scheduled RALPN as opposed to radical nephrectomy or other techniques for partial nephrectomy such as open surgery or pure laparoscopy without robot assistance.
- Patients with bilateral kidneys or a solitary kidney, so long as these are native kidneys as opposed to a transplanted kidney.
- Patients can have the common single renal artery and single renal vein, or they can have common variants such as two renal arteries and/or two renal veins.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University Of Chicago Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
Related publications
- Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy.J Urol · 2026 · PMID 41360001
This page is information, not medical advice. Discuss any trial with your doctor.